Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
Clinical trial NCT07463768 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07463768
- Sponsor
- French Innovative Leukemia Organisation
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2030-09-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.